AVITA MEDICAL INC (RCEL) Fundamental Analysis & Valuation

NASDAQ:RCEL • US05380C1027

Current stock price

4.62 USD
-0.05 (-1.07%)
Last:

This RCEL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RCEL Profitability Analysis

1.1 Basic Checks

  • In the past year RCEL has reported negative net income.
  • In the past year RCEL has reported a negative cash flow from operations.
  • RCEL had negative earnings in each of the past 5 years.
  • In the past 5 years RCEL always reported negative operating cash flow.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • RCEL's Return On Assets of -86.16% is on the low side compared to the rest of the industry. RCEL is outperformed by 71.71% of its industry peers.
Industry RankSector Rank
ROA -86.16%
ROE N/A
ROIC N/A
ROA(3y)-65.15%
ROA(5y)-48.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • RCEL has a Gross Margin of 83.27%. This is amongst the best in the industry. RCEL outperforms 86.05% of its industry peers.
  • In the last couple of years the Gross Margin of RCEL has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for RCEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y0.47%
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. RCEL Health Analysis

2.1 Basic Checks

  • RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RCEL has more shares outstanding
  • Compared to 5 years ago, RCEL has more shares outstanding
  • The debt/assets ratio for RCEL is higher compared to a year ago.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • RCEL has an Altman-Z score of -10.68. This is a bad value and indicates that RCEL is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -10.68, RCEL is doing worse than 74.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.68
ROIC/WACCN/A
WACC10.43%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • RCEL has a Current Ratio of 0.57. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
  • RCEL has a Current ratio of 0.57. This is amonst the worse of the industry: RCEL underperforms 91.67% of its industry peers.
  • A Quick Ratio of 0.46 indicates that RCEL may have some problems paying its short term obligations.
  • RCEL has a Quick ratio of 0.46. This is amonst the worse of the industry: RCEL underperforms 92.05% of its industry peers.
Industry RankSector Rank
Current Ratio 0.57
Quick Ratio 0.46
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RCEL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 26.78% over the past year.
  • RCEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.45%.
  • The Revenue has been growing by 38.09% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
Revenue 1Y (TTM)11.45%
Revenue growth 3Y27.66%
Revenue growth 5Y38.09%
Sales Q2Q%-4.29%

3.2 Future

  • Based on estimates for the next years, RCEL will show a very strong growth in Earnings Per Share. The EPS will grow by 32.69% on average per year.
  • The Revenue is expected to grow by 36.14% on average over the next years. This is a very strong growth
EPS Next Y49.97%
EPS Next 2Y25.34%
EPS Next 3Y38.68%
EPS Next 5Y32.69%
Revenue Next Year15.44%
Revenue Next 2Y31.51%
Revenue Next 3Y47.36%
Revenue Next 5Y36.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. RCEL Valuation Analysis

4.1 Price/Earnings Ratio

  • RCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • RCEL's earnings are expected to grow with 38.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.34%
EPS Next 3Y38.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RCEL Dividend Analysis

5.1 Amount

  • No dividends for RCEL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RCEL Fundamentals: All Metrics, Ratios and Statistics

AVITA MEDICAL INC

NASDAQ:RCEL (4/23/2026, 10:59:23 AM)

4.62

-0.05 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-13
Earnings (Next)05-07
Inst Owners15.81%
Inst Owner Change0.82%
Ins Owners1.38%
Ins Owner Change19.51%
Market Cap141.51M
Revenue(TTM)71.61M
Net Income(TTM)-48.59M
Analysts80
Price Target6.53 (41.34%)
Short Float %12.66%
Short Ratio16.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.84%
Min EPS beat(2)-58.8%
Max EPS beat(2)-10.88%
EPS beat(4)0
Avg EPS beat(4)-38.71%
Min EPS beat(4)-58.8%
Max EPS beat(4)-10.88%
EPS beat(8)1
Avg EPS beat(8)-32.32%
EPS beat(12)3
Avg EPS beat(12)-22.95%
EPS beat(16)7
Avg EPS beat(16)-10.85%
Revenue beat(2)0
Avg Revenue beat(2)-4.57%
Min Revenue beat(2)-8.01%
Max Revenue beat(2)-1.13%
Revenue beat(4)0
Avg Revenue beat(4)-10.85%
Min Revenue beat(4)-20.13%
Max Revenue beat(4)-1.13%
Revenue beat(8)1
Avg Revenue beat(8)-7.42%
Revenue beat(12)4
Avg Revenue beat(12)-5.12%
Revenue beat(16)8
Avg Revenue beat(16)-0.27%
PT rev (1m)3.23%
PT rev (3m)-7.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.54%
EPS NY rev (1m)-11.23%
EPS NY rev (3m)-4.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.98
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS2.34
BVpS-0.54
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -86.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.27%
FCFM N/A
ROA(3y)-65.15%
ROA(5y)-48.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y0.47%
F-Score3
Asset Turnover1.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69.88%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.57
Quick Ratio 0.46
Altman-Z -10.68
F-Score3
WACC10.43%
ROIC/WACCN/A
Cap/Depr(3y)367.62%
Cap/Depr(5y)268.86%
Cap/Sales(3y)6.44%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
EPS Next Y49.97%
EPS Next 2Y25.34%
EPS Next 3Y38.68%
EPS Next 5Y32.69%
Revenue 1Y (TTM)11.45%
Revenue growth 3Y27.66%
Revenue growth 5Y38.09%
Sales Q2Q%-4.29%
Revenue Next Year15.44%
Revenue Next 2Y31.51%
Revenue Next 3Y47.36%
Revenue Next 5Y36.14%
EBIT growth 1Y26.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.65%
EBIT Next 3Y35.15%
EBIT Next 5Y24.79%
FCF growth 1Y43.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.26%
OCF growth 3YN/A
OCF growth 5YN/A

AVITA MEDICAL INC / RCEL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCEL.


What is the valuation status of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a valuation rating of 1 / 10 to AVITA MEDICAL INC (RCEL). This can be considered as Overvalued.


What is the profitability of RCEL stock?

AVITA MEDICAL INC (RCEL) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for RCEL stock?

The Earnings per Share (EPS) of AVITA MEDICAL INC (RCEL) is expected to grow by 49.97% in the next year.